Clinical Trials
Panic Disorder
The effectiveness of Clonazepam in the treatment of panic disorder was demonstrated in two double-blind, placebo-controlled studies of adult outpatients who had a primary diagnosis of panic disorder (DSM-IIIR) with or without agoraphobia. In these studies, Clonazepam was shown to be significantly more effective than placebo in treating panic disorder on change from baseline in panic attack frequency, the Clinician’s Global Impression Severity of Illness Score and the Clinician’s Global Impression Improvement Score.
Study 1 was a 9 week, fixed-dose study involving Clonazepam doses of 0.5, 1, 2, 3 or 4 mg/day or placebo. This study was conducted in four phases: a 1 week placebo lead-in, a 3 week upward titration, a 6 week fixed dose and a 7 week discontinuance phase.
A significant difference from placebo was observed consistently only for the 1 mg/day group. The difference between the 1 mg dose group and placebo in reduction from baseline in the number of full panic attacks was approximately 1 panic attack per week.
At endpoint, 74% of patients receiving Clonazepam 1 mg/day were free of full panic attacks, compared to 56% of placebo-treated patients.
Study 2 was a 6 week, flexible-dose study involving Clonazepam in a dose range of 0.5 to 4 mg/day or placebo. This study was conducted in three phases: a 1 week placebo lead-in, a 6 week optimal-dose and a 6 week discontinuance phase.
The mean Clonazepam dose during the optimal dosing period was 2.3 mg/day. The difference between Clonazepam and placebo in reduction from baseline in the number of full panic attacks was approximately 1 panic attack per week.
At endpoint, 62% of patients receiving Clonazepam were free of full panic attacks, compared to 37% of placebo-treated patients.
http://www.drugs.com/pro/clonazepam.html